The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017)
Current Oncology · 2023
DOI: 10.3390/curroncol30040329 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Emily V Walker und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University of Alberta, Edmonton, AB T6G 1C9, Canada. Hauptthemen laut MEDLINE: Glioblastoma, Meningioma, Central Nervous System Neoplasms, Meningeal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brain Tumour Foundation of Canada.
Abstract (Originalsprache)
Primary central nervous system (CNS) tumours are heterogeneous, with different treatment pathways and prognoses depending on their histological and molecular classification. Due to their anatomical location, all CNS tumours, regardless of malignancy, can be debilitating. We used vital statistics linked to Canadian Cancer Registry data to estimate the age-standardized incidence rates (ASIR), Kaplan–Meier survival rates (SR), and limited-duration prevalence proportions (PP) of 25 histology-specific CNS tumour groups that were classified based on site and histology. During 2010–2017, 45,115 patients were diagnosed with 47,085 primary CNS tumours, of which 19.0% were unclassified. The average annual ASIR was 21.48/100,000 person-years and did not vary by sex. The ASIR increased with age, particularly for meningioma, unclassified tumours, and glioblastoma. The eight-year PP was 102.1/100,000 persons (index date 1 January 2018). The most common histology was meningioma (ASIR: 5.19; PP: 31.6). The overall five-year SR among 51,310 patients diagnosed during 2008–2017 was 57.2% (95% CI: 56.8–57.7%). SRs varied by tumour behaviour, histology, and patient age, with the lowest SR among glioblastoma patients (5-year SRs ranged from 1.3–25.7%). For non-malignant tumours, the 5-year SRs ranged from 37.4–100%. We provide the most up-to-date histology-specific surveillance estimates for primary CNS tumours in Canada.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Public Health, University of Alberta, Edmonton, AB T6G 1C9, Canada.
- Precision Analytics, Cancer Research & Analytics, Cancer Care Alberta, Alberta Health Services, Edmonton, AB T5J 3C6, Canada.
- Department of Oncology, Western University, London, ON N6A 5W9, Canada.
ORCID-Profile: Seth A Climans, Yan Yuan
Förderung
- Brain Tumour Foundation of Canada
Zitieren
APA
Walker, E. V., Zhou, Y., Wu, Y., Liu, J., Climans, S. A., Davis, F. G., & Yuan, Y. (2023). The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017). Current Oncology. https://doi.org/10.3390/curroncol30040329
Vancouver
Walker EV, Zhou Y, Wu Y, Liu J, Climans SA, Davis FG, et al. The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017). Current Oncology. 2023. doi:10.3390/curroncol30040329
BibTeX
@article{Walker2023,
author = {Walker, Emily V and Zhou, Yiling and Wu, Yifan and Liu, Jiaqi and Climans, Seth A and Davis, Faith G and Yuan, Yan},
title = {The Incidence and Prevalence of Primary Central Nervous System (CNS) Tumours in Canada (2010–2017), and the Survival of Patients Diagnosed with CNS Tumours (2008–2017)},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30040329}
}
EUVIMED